|
1
|
Shields CL and Shields JA: Retinoblastoma
management: advances in enucleation, intravenous chemoreduction,
and intra-arterial chemotherapy. Curr Opin Ophthalmol. 21:203–212.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jabbour P, Chalouhi N, Tjoumakaris S,
Gonzalez LF, Dumont AS, Chitale R, Rosenwasser R, Bianciotto CG and
Shields C: Pearls and pitfalls of intraarterial chemotherapy for
retinoblastoma. J Neurosurg Pediatr. 10:175–181. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kivelä T: The epidemiological challenge of
the most frequent eye cancer: Retinoblastoma, an issue of birth and
death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Malan-Müller S, Hemmings SM and Seedat S:
Big effects of small RNAs: A review of microRNAs in anxiety. Mol
Neurobiol. 47:726–739. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Fabian MR, Sonenberg N and Filipowicz W:
Regulation of mRNA translation and stability by microRNAs. Annu Rev
Biochem. 79:351–379. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Guo H, Ingolia NT, Weissman JS and Bartel
DP: Mammalian microRNAs predominantly act to decrease target mRNA
levels. Nature. 466:835–840. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
McManus MT: MicroRNAs and cancer. Semin
Cancer Biol. 13:253–258. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Y and Mei Q: miRNA signature
identification of retinoblastoma and the correlations between
differentially expressed miRNAs during retinoblastoma progression.
Mol Vis. 21:1307–1317. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Beta M, Venkatesan N, Vasudevan M,
Vetrivel U, Khetan V and Krishnakumar S: Identification and
insilico analysis of retinoblastoma serum microRNA profile and gene
targets towards prediction of novel serum biomarkers. Bioinform
Biol Insights. 7:21–34. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pei YF, Lei Y and Liu XQ: MiR-29a promotes
cell proliferation and EMT in breast cancer by targeting ten eleven
translocation 1. Biochim Biophys Acta. 1862:2177–2185. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu Z, Cui Y, Zhou Y, Zhou K, Qiao X, Li C
and Wang S: MicroRNA-29a plays a suppressive role in non-small cell
lung cancer cells via targeting LASP1. Onco Targets Ther.
9:6999–7009. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tang W, Zhu Y, Gao J, Fu J, Liu C, Liu Y,
Song C, Zhu S, Leng Y, Wang G, et al: MicroRNA-29a promotes
colorectal cancer metastasis by regulating matrix metalloproteinase
2 and E-cadherin via KLF4. Br J Cancer. 110:450–458. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He B, Xiao YF, Tang B, Wu YY, Hu CJ, Xie
R, Yang X, Yu ST, Dong H, Zhao XY, et al: hTERT mediates gastric
cancer metastasis partially through the indirect targeting of ITGB1
by microRNA-29a. Sci Rep. 6:219552016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mahati S, Xiao L, Yang Y, Mao R and Bao Y:
miR-29a suppresses growth and migration of hepatocellular carcinoma
by regulating CLDN1. Biochem Biophys Res Commun. 486:732–737. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li R, Liu J, Li Q, Chen G and Yu X:
miR-29a suppresses growth and metastasis in papillary thyroid
carcinoma by targeting AKT3. Tumour Biol. 37:3987–3996. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cheng Y, Li Y, Nian Y, Liu D, Dai F and
Zhang J: STAT3 is involved in miR-124-mediated suppressive effects
on esophageal cancer cells. BMC Cancer. 15:3062015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu S, Hu C, Wang Y, Shi G, Li Y and Wu H:
miR-124 inhibits proliferation and invasion of human retinoblastoma
cells by targeting STAT3. Oncol Rep. 36:2398–2404. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu X, Zeng Y, Wu S, Zhong J, Wang Y and Xu
J: MiR-204, down-regulated in retinoblastoma, regulates
proliferation and invasion of human retinoblastoma cells by
targeting Cyclin D2 and MMP-9. FEBS Lett. 589:645–650. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martin A, Jones A, Bryar PJ, Mets M,
Weinstein J, Zhang G and Laurie NA: MicroRNAs-449a and −449b
exhibit tumor suppressive effects in retinoblastoma. Biochem
Biophys Res Commun. 440:599–603. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gui F, Hong Z, You Z, Wu H and Zhang Y:
MiR-21 inhibitor suppressed the progression of retinoblastoma via
the modulation of PTEN/PI3K/AKT pathway. Cell Biol Int.
40:1294–1302. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mott JL, Kurita S, Cazanave SC, Bronk SF,
Werneburg NW and Fernandez-Zapico ME: Transcriptional suppression
of mir-29b-1/mir-29a promoter by c-Myc, hedgehog, and NF-kappaB. J
Cell Biochem. 110:1155–1164. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Catela Ivkovic T, Voss G, Cornella H and
Ceder Y: microRNAs as cancer therapeutics: A step closer to
clinical application. Cancer Lett. 407:113–122. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Turkson J: STAT proteins as novel targets
for cancer drug discovery. Expert Opin Ther Targets. 8:409–422.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chai EZ, Shanmugam MK, Arfuso F,
Dharmarajan A, Wang C, Kumar AP, Samy RP, Lim LH, Wang L, Goh BC,
et al: Targeting transcription factor STAT3 for cancer prevention
and therapy. Pharmacol Ther. 162:86–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Masuda M, Suzui M, Yasumatu R, Nakashima
T, Kuratomi Y, Azuma K, Tomita K, Komiyama S and Weinstein IB:
Constitutive activation of signal transducers and activators of
transcription 3 correlates with Cyclin D1 overexpression and may
provide a novel prognostic marker in head and neck squamous cell
carcinoma. Cancer Res. 62:3351–3355. 2002.PubMed/NCBI
|
|
27
|
Kim BH, Yi EH and Ye SK: Signal transducer
and activator of transcription 3 as a therapeutic target for cancer
and the tumor microenvironment. Arch Pharm Res. 39:1085–1099. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cafferkey C and Chau I: Novel STAT 3
inhibitors for treating gastric cancer. Expert Opin Investig Drugs.
25:1023–1031. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jo DH and Kim JH, Cho CS, Cho YL, Jun HO,
Yu Y, Min JK and Kim JH: STAT3 inhibition suppresses proliferation
of retinoblastoma through down-regulation of positive feedback loop
of STAT3/miR-17-92 clusters. Oncotarget. 5:11513–11525. 2014.
View Article : Google Scholar : PubMed/NCBI
|
